The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Abstract
Background Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs. Methods This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity. We performed frequentist random-effect network meta-analyses to summarise the evidence and applied the Grading of Recommendations Assessment, Development, and Evaluation frameworks to rate the certainty of evidence, calculate the absolute effects, categorise interventions, and present the findings. The study was registered with PROSPERO, CRD 42021245678. Findings 14 605 citations were identified by our search, of which 132 eligible trials enrolled 48 209 participants. All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification. High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of ≥5% weight reduction 8·02, 95% CI 5·24 to 12·27; mean difference [MD] of percentage bodyweight change -7·98, 95% CI -9·27 to -6·69) followed by GLP-1 receptor agonists (OR 6·33, 95% CI 5·00 to 8·00; MD -5·79, 95% CI -6·34 to -5·25). Naltrexone-bupropion (OR 2·69, 95% CI 2·10 to 3·44), phentermine-topiramate (2·40, 1·68 to 3·44), GLP-1 receptor agonists (2·22, 1·74 to 2·84), and orlistat (1·71, 1·42 to 2·05) were associated with increased adverse events leading to drug discontinuation. In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95% CI -12·51 to -10·29). Interpretation In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective. Funding 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, incretin hormone‐based drugs, first and foremost glucagon‐like peptide 1 receptor agonists (GLP‐1RA), 11 have emerged as a pivotal treatment option for managing both obesity and T2D. 12 , 13 , 14 , 15”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [15]
In the citing paper
“The three GLP‐1RA‐based agents currently approved for weight loss have all shown clear efficacy in promoting weight loss in randomized controlled trials (RCTs), 17 , 18 , 19 that is, in settings with good medication adherence among participants and a follow‐up of typically one to two years. 15”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [15]
In the citing paper
“In a 2024 network meta-analysis of 61 randomized controlled trials (RCTs) comparing active treatments to lifestyle modification in adults with overweight or obesity, both phentermine-topiramate (odds ratio [OR]: 2.40, 95% CI 1.68, 3.44) and naltrexone-bupropion (OR: 2.69, 95% CI 2.10, 3.44) ranked among the highest for treatment discontinuation due to adverse events.14”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [14]
In the citing paper
“In contrast, GLP-1 RAs have primarily been associated with gastrointestinal side effects and have demonstrated more favorable psychiatric and cardiovascular safety profiles.13,14”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [14]
In the citing paper
“Several NMAs20–23 and a traditional meta-analysis24 on different therapeutic options for overweight and obesity were published in the last few years, but they did not include more recently available OMMs, such as tirzepatide20–22, or they included medications not approved for the treatment of overweight/obesity (for example, metformin, SGLT2 inhibitors or GLP-1 agonists, such as dulaglutide)22, or”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [22]
In the citing paper
“These results are in line with those reported in previous NMA and meta-analysis20–22,24”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [22]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812
Self-citation
Cited by
Sorted by citations
Items 101–170 of 170
Ghani, R. A., Mukhtar, F., Yusof, B. N. M., & Hanipah, Z. N. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13867-3 · Cited by 1
Evidence contributions in component network meta-analysis from the shortest-path approach
Yang, Q., Shen, Y., Mao, Y., & Li, S. (2026) · BMC Medical Research Methodology · doi:10.1186/s12874-026-02766-8 · Cited by 1
Self-citationMack, I., Kullmann, S., de Sequeira, C. L. M., Klos, B., Zipfel, S., Birkenfeld, A. L., & Erschens, R. S. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10047-4 · Cited by 2
Yeh, K.-H., Ahuja, D., Patel, S. B., Xu, R., Park, S.-K., Gold, S. L., Ramos, G. P., Malik, T., Kaur, M., Bering, J., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.06.008 · Cited by 1
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 1
Lappin, J., Bolton, P., Smith, G., Chua, X., Grattan, S., Samaras, K., Day, R., Popovic, G. C., O׳Donnell, M., Buten, S., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.021 · Cited by 1
Skandov, M. D., Christensen, K. M., Dalin, D. A., Unkerskov, J., Brønden, A., Lund, M. A. V., Christensen, M., & Karstoft, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71092 · Cited by 1
Jiang, J., Liang, Y., Wang, R., Jiang, W., Jing, X., & Yang, M. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70343 · Cited by 1
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1
Li, L., & Hao, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1944242 · Cited by 1
Self-citationTrends in cardiometabolic risk factors according to body mass index in Peru between 2015 and 2023
Carrillo-Larco, R. M., & Bernabé‐Ortiz, A. (2025) · Annals of Epidemiology · doi:10.1016/j.annepidem.2025.03.006 · Cited by 1
Wee, C. C., Li, T., Batch, B. C., & Wong, J. B. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01972 · Cited by 1
Response to “Response to review by Pan et al.”
Pan, X., Chin, Y. H., Chan, M. Y., & Chew, N. W. S. (2024) · Obesity · doi:10.1002/oby.24087
Sachs, V., Jalkh, A. P. C., Macedo, D. D., & Jamaleddine, M. (2025) · Evidence-Based Practice · doi:10.1097/ebp.0000000000002354
A Revolution in Medicine and Surgery Has Begun
Spector, R. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.02.012
Marmett, B., da Silva, I., Lira, F. S., & Dorneles, G. P. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2024-0039
Bianchi, M. E. (2025) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2025.151604
Xue, Y., Song, M., Yu, H., Chen, X., Ung, C. O. L., & Hu, H. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s501149
de Oliveira, S. C., Pontes, M. R., Bianchini, L. B., Búrigo, J. H., Michelutti, L. M. D., Schroff, W. L. A., Chaves, A., Schroff, K. J. E., dos Santos, H. B., & Loureiro, T. (2025) · International Journal of Nutrology · doi:10.54448/ijn25s303
Systematic review of clinical outcomes of anorexigenic treatment of obesity
Schroff, K. J. E., dos Santos, H. B., Bianchini, L. B., Búrigo, J. H., Michelutti, L. M. D., Pontes, M. R., Schroff, W. L. A., Chaves, A., Loureiro, T., & de Oliveira, S. C. (2025) · International Journal of Nutrology · doi:10.54448/ijn25s306
Xiao, X., Xu, Y., Lang, X., Zhang, T., Yang, F., Ding, Z., Shen, X., Zhao, C., Guo, N., & Ye, H. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250689
Gianopoulos, I., & Daskalopoulou, S. S. (2025) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2025.08.002
Obesity and musculoskeletal pain: possibilities of pharmacotherapy. A narrative overview
Karateev, A. E., & Zotkin, E. G. (2025) · Russian Journal of Pain · doi:10.17116/pain20252303173
Deusch, K., Deboek, A., Sina, C., Capó-Vélez, C. M., Alicea, V., Duller, S., Grafe, S., Lidington, D., Hanchard, J., & Bolz, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70135
Li, P., He, C. S., Wu, C., Zhou, X., Ma, Y., & Deng, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-20719-x
Liu, K.-H., Chen, I., & Lin, W.-R. (2025) · Springer eBooks · doi:10.1007/978-981-95-2648-2_11
Exploring Endothelial Injury Syndromes: Mechanisms, Markers, and Therapeutic Potential
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7154-5
Pharmacological management of binge eating disorder
Williams, A. M. (2025) · Mental Health Clinician · doi:10.9740/mhc.2025.12.285
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803
Holistic Approaches to Understanding Obesity and Metabolic Diseases in Urban Environments
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7253-5
Semaglutide: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara45190890
Li, X.-X., Hu, Z., Yuan, D.-N., Zhao, J.-X., Ma, W.-B., & Lan, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s553787
Weight Loss-Associated Alopecia Areata
Cheng, J.-R., Zheng, J., Li, Y., Shi, H., Yang, N., Lei, Y., & Wan, Y. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001851
Self-citationTreatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
Hass, D., Madsen, A. N., da Silva‐Buttkus, P., Kjølbye, A. L., Støy, S. H., Nøhr-Meldgaard, J., Sandahl, T. D., de Angelis, M. H., Jørgensen, R., Rohm, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.041
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
Wang, Y., Liu, T., Cheng, J., Feng, J., Ding, J., Ji, Y., Zhao, R., Huo, J., Gong, Z., & Zhuo, Q. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1774209
Self-citationThe leptin fragment Lep116-130 attenuates hedonic consumption and sucrose-seeking in mice
Ramírez-Romero, R., Jiménez, Y., Kerr, B., Dinamarca‐Villarroel, L., Robles, A. I., Llanos, P., Montaña, P., Cortés, V., Perez‐Leighton, C. E., & Baudrand, R. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1748508
Yamamoto, J., Abreu-Rosario, C., Arellano, R., Martinez, C. O., Morales, A., Sánchez-Mijangos, J. H., Vázquez-García, J., Violante-Ortiz, R. M., Zarza, P., Ceron-Trujillo, B., et al. (2026) · Obesities · doi:10.3390/obesities6020018
Vásquez-Tirado, G. A., Villarreal-Jara, M., Meregildo-Rodríguez, E. D., & Quispe-Castañeda, C. V. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100697
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
Nair, V. (2026) · Springer eBooks · doi:10.1007/978-3-032-17118-4_5
Pharmacological interventions for the treatment of obesity in children and adolescents
Gerardi, C., Allocati, E., Prutsky, G. J., Carrano, F. M., Romano, E., Giorgi, S. D., Metzendorf, M., Calcaterra, V., Lorenzo, N. D., & Banzi, R. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015986
Du, D., He, S., Guo, S., Liao, Y., Qin, J., Chen, Z., Liu, S., Luo, F., Shen, Y., & Wen, F. (2026) · Public Health · doi:10.1016/j.puhe.2026.106349
Self-citationPrevalence of economic burden of overweight and obesity and their associated factors in Saudi Arabia
Zafar, M., Albrahimi, A. A., & Alanezi, N. M. S. (2026) · Asian Biomedicine · doi:10.2478/abm-2026-0013
López-Delgado, D. S., Diaz, M. P., Escalona, D., Dorante, I. C. P., Zambrano, F., Rivera-Porras, D., & Bermúdez, V. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag088
Weight Gains Across Adulthood—The ELSA ‐Brasil Study
Canhada, S., Bracco, P. A., da Fonseca, M. D. J. M., Molina, M. D. C., Schmidt, M. I., & Duncan, B. B. (2026) · Clinical Obesity · doi:10.1111/cob.70095
Clinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Guo, W., Zhao, M. H., Liu, Y., Zhang, X., & Liu, G. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s599084
Self-citationNi, W., Li, J., Bai, X., Sisi, Z., Wu, X., Jia, L., Jiang, Z., Wu, J., Li, M., Wong, H.-N., et al. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00596
Self-citationRadacher, L., Zaussinger, M., Ehebruster, G., Bachleitner, K., Feldler, S., Schwartz, B., & Schmidt, M. (2026) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012633
Obstructive sleep apnea pharmacology
Sunwoo, B. Y., Schmickl, C. N., & Malhotra, A. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2695024
Kopniak, W., Konopko, S., Góra, K., Wasilewska, W., Buszta, B., Kokuszko, I., & Markiewicz, M. (2026) · Quality in Sport · doi:10.12775/qs.2026.67.74311
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Şahi̇n, F., Karamzad, N., Aletaha, R., Tahmasbi, F., Amiri, F., Sullman, M. J. M., Grieger, J. A., & Safiri, S. (2026) · Adipocyte · doi:10.1080/21623945.2026.2716431
Gilardini, L., Vincenti, V., Croci, M., Martinelli, S., Pasqualinotto, L., Toja, P. M., Cavaggioni, L., & Bertoli, S. (2026) · Journal of Obesity · doi:10.1155/jobe/1224246
Lei, W., Tripathi, A., & Hu, S. (2026) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-171105
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
Klotz, T. (2026) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2943-1080
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Chen, Y., Zhang, Y., Song, Y., Xing, H., Luo, Y., Lai, Y., Li, Y., & Dong, Z. (2026) · Obesity Reviews · doi:10.1111/obr.70232
Self-citationAmjad, M. M., Khan, M. M., Sarwar, F., Ali, A., Ali, M., Bakhash, F., Abid, H., Ibrahim, F., Mustafa, K., Ali, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71400
Yacaman, G. J. P., López, A. M. J., Cordova, P. R., Cuenca, S. E. A., López, S. M., Lladó, A. I. C., Quintero, D. O. B., Bárcena, E. D. C., Mottú, R. A. Z., Flores, V. Z., et al. (2026) · Cureus · doi:10.7759/cureus.117774
Ciapponi, A. (2026) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v29i4.7259
Tauekelova, A., Karipova, B., Zholdybaeva, A., Khamitov, S., Jetybayeva, S., Tuyakova, G., Samatkyzy, D., Sarbassov, D. D., Akilzhanova, A. R., & Asanova, A. (2026) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/19277
Tirzepatide-Associated Lithium Toxicity
Davis, J., Singhal, S., & Butterfield, A. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002271
Future directions in obesity pharmacotherapy: Novel targets and pipeline therapies
Mauer, Y., & Isaacs, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.003
Gędek, A., Modrzejewski, S., Polański, K., Waśniewska, L., Molero, P., Wichniak, A., Dominiak, M., & McIntyre, R. S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113886
Pediatric obesity pharmacotherapy: a practical guide for general pediatricians
Mulvihill, H., Pliskin, L., Ponery, N., & Katzow, M. W. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001621
Li, Y., 陈彩云, Shang, B., Zhao, T., Zhao, Y., Li, J., Wang, K., Huang, J., Liu, Z., Zhou, F., et al. (2026) · Food Research International · doi:10.1016/j.foodres.2026.121073
Self-citation
Metadata
- Authors
- Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., Sun, F., Li, L., Yu, J., Nong, K., Zou, X., Zhu, S., Wang, C., Zhang, S., Qiao, Z., Jian, Z., Li, Y., Zhang, X., Chen, K., Qu, F., Wu, Y., He, Y., Tian, H., & Li, S.
- Affiliations
- Sichuan University (CN)
- Lovisenberg Diakonale Sykehus (NO)
- McMaster University (CA)
- Tianjin University of Traditional Chinese Medicine (CN)
- Lanzhou University (CN)
- Peking University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Corresponding author
- Li, Sheyu
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 403
- Issue
- 10434
- Pages
- e21-e31
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4393952591
- Cited by
- 155
- References
- 43
- Citations by year
- 2026: 60 · 2025: 67 · 2024: 27
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-04-06)
- Open access
- closed
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- West China Hospital, Sichuan University (ZYGD18022, 2020HXF011)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- pharmacotherapy, obesity, overweight, phentermine/topiramate, GLP-1 receptor agonists, semaglutide, naltrexone/bupropion, orlistat, lifestyle modification, weight loss, adverse events, drug discontinuation, adults, GRADE certainty of evidence
- MeSH terms
- Network Meta-Analysis, Topiramate, Adult, Humans, Obesity, Phentermine, Weight Loss, Randomized Controlled Trials as Topic, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
